Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi ( (SNY) ) has shared an announcement.
In September 2025, Sanofi announced that its gene therapy SAR446268 received fast track designation from the US FDA for treating non-congenital myotonic dystrophy type 1, a rare genetic disorder with no approved treatments. This designation aims to expedite the development of SAR446268, which uses RNA interference to target the DMPK gene, potentially addressing key symptoms of the disease. Additionally, Sanofi committed an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation, reinforcing its strategic focus on advancing healthcare solutions.
The most recent analyst rating on (SNY) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by its strong earnings call performance and attractive valuation, which are offset by bearish technical indicators and moderate financial performance. The company’s strategic initiatives and positive sales outlook contribute significantly to its score, despite some challenges in cash flow and market momentum.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines. The company leverages its deep understanding of the immune system to address urgent healthcare challenges and is listed on EURONEXT: SAN and NASDAQ: SNY.
Average Trading Volume: 2,586,710
Technical Sentiment Signal: Sell
Current Market Cap: $113.1B
Learn more about SNY stock on TipRanks’ Stock Analysis page.